Home   |   Contact   |

Share |

Press Releases

April 13, 2012

Rib-X Pharmaceuticals Appoints Infectious Disease Expert and Former FDA Deputy Director Matthew Wikler, MD as Chief Development Officer

 

February 7, 2012

Rib-X Pharmaceuticals Receives $3 Million Milestone Payment from Sanofi in the RX-04 Collaboration

 

December 15, 2011

Rib-X Reports Positive Top-Line Data from Phase 2b Study of Delafloxacin in Patients with Acute Bacterial Skin and Skin Structure Infections 

 

November 28, 2011

Rib-X Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering

 

October 21, 2011

Rib-X Pharmaceuticals' RX-04 Program Yields Compounds with In Vitro Potency Against Multi-drug Resistant P. aeruginosa 

 

September 20, 2011

Rib-X Pharmaceuticals Presents Comprehensive Overview of RX-04 Program in 14 Posters at ICAAC

 

September 8, 2011

Rib-X Pharmaceuticals to Present 16 Posters Highlighting Data from its Antibiotic Development Programs at ICAAC

 

September 7, 2011

Rib-X Announces Senior Management Promotions

 

September 6, 2011

Rib-X Pharmaceuticals Named a 2011 Fierce 15 Company by FierceBiotech

 

July 19, 2011

Rib-X Pharmaceuticals Receives $9 Million Milestone Payment from Sanofi in the RX-04 Collaboration

 

July 6, 2011

Rib-X Pharmaceuticals and Sanofi Sign a Research Collaboration Agreement on Novel Classes of Antibiotics

 

June 15, 2011

Rib-X Pharmaceuticals Supports Generating Antibiotic Incentives Now (GAIN) Act

 

May 9, 2011

Rib-X Pharmaceuticals Presents Data at ECCMID Demonstrating Potent In Vitro Activity of Radezolid and Delafloxacin Against Resistant Strains of Gram-positive Bacteria Program

 

May 9, 2011

Rib-X Pharmaceuticals Presents Data at ECCMID for Three Novel Classes of Broad-spectrum Antibiotic Compounds From the RX-04 Development Program

 

May 3, 2011

Rib-X Pharmaceuticals to Present Six Abstracts at 21st Annual ECCMID/ 27th Annual ICC Conference

 

April 13, 2011

Rib-X Pharmaceuticals to Present at the Future Leaders in the Biotech Industry Conference

 

March 16, 2011

Rib-X Pharmaceuticals to Present at 13th Annual Superbugs & Superdrugs Conference

 

February 8, 2011

Rib-X Initiates Phase 2b Study for Broad Spectrum Antibiotic Candidate Delafloxacin in Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

 

January 11, 2011

Rib-X Pharmaceuticals Raises $20 Million to Advance its Industry-Leading Antibiotics Pipeline

 

January 6, 2011

Rib-X Announces Publication Demonstrating Superior Infection Site Potency for Delafloxacin against Gram-positive Pathogens

 

 

Home      |      Contact      |      Terms      |      Site Map      |      © 2012 Rib-X Pharmaceuticals, Inc.    All Rights Reserved.